Quarterly report pursuant to Section 13 or 15(d)

Stock-Based Compensation, Restricted Stock and Stock Options: (Tables)

v3.20.1
Stock-Based Compensation, Restricted Stock and Stock Options: (Tables)
 6 Months Ended
Sep. 30, 2019
Share-based Payment Arrangement [Abstract]  
Schedule of stock based compensation expenses
    Three months ended
September 30,		     Six months ended
September 30,		  
    2019     2018     2019     2018  
                         
Research and development expenses   $ 722,606     $ 115,290     $ 981,515     $ 232,846  
Selling, general and administrative expenses     1,046,816       115,707       1,884,850       204,286  
Total stock-based compensation   $ 1,769,422     $ 230,997     $ 2,866,365     $ 437,132  
Schedule of restricted stock awards
    Number of Shares     Weighted Average Grant-Date
 Fair Value		  
Unvested at March 31, 2019     -     $ -  
Granted     6,000,000     $ 0.82  
Vested     (749,997 )   $ 0.82  
Unvested at September 30, 2019 (Unaudited)     5,250,003     $ 0.82  
Schedule of stock options
    Shares Underlying Options     Weighted Average Exercise Price     Weighted Average Remaining Contractual
 Term (Years)		     Aggregate Intrinsic Value  
Outstanding at March 31, 2019     5,813,500     $ 0.18       9.2     $ 3,720,395  
Outstanding at September 30, 2019 (Unaudited)     5,813,500     $ 0.18       8.7     $ 3,313,450  
                                 
Exercisable at September 30, 2019 (Unaudited)     2,560,092     $ 0.19       8.7     $ 1,435,611